


DOI: 10.1038/s41467-017-02205-9

OPEN

Author Correction: Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent

Pengju Wang¹, Xiaozhu Li², Jiwei Wang¹, Dongling Gao¹, Yuenan Li¹, Haoze Li¹, Yongchao Chu¹, Zhongxian Zhang¹, Hongtao Liu¹, Guozhong Jiang¹, Zhenguo Cheng¹, Shengdian Wang², Jianzeng Dong³, Baisui Feng^{1,4}, Louisa S Chard⁵, Nicholas R Lemoine^{1,5} & Yaohe Wang^{1,5} 

Nature Communications <https://doi.org/10.1038/s41467-017-01385-8>, Article published online 9 November 2017

The originally published version of this Article contained errors in Figure 4. In panel b, the square and diamond labels associated with the uppermost survival curve were incorrectly displayed as 'n' and 'u', respectively. These errors have now been corrected in both the PDF and HTML versions of the Article.

Published online: 10 January 2018



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2018

¹Sino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou 450052, China. ²CAS Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China. ³Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China. ⁴Section of Digestive Diseases, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450014, China. ⁵Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK. Correspondence and requests for materials should be addressed to Y.W. (email: yaohe.wang@qmul.ac.uk)